Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: Low risk of gastrointestinal and cardiovascular toxicity

European Journal of Gynaecological Oncology

Volumn 31, Issue 3, 2010, Pages 308-311

  Abaid, L N ^a   Lopez, K L ^b   Micha, J P ^a   Rettenmaier, M A ^a   Brown III, J V ^a   Goldstein, B H ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Women's Cancer Research Foundation   (United States)

Author keywords

Bevacizumab; Bowel perforation; Gynecologic oncology; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; INTESTINAL PERFORATION; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; RISK;

EID: 77954110165     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J.: "Cancer Statistics, 2007". CA Cancer J. Clin., 2007, 57, 43.
2. Hansen S.W.: "Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma". Semin. Oncol., 2002, 29, 17.
3. de Gramont A., Van Cutsem E.: "Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer". Oncology, 2005, 69, 46.
4. Rasila K.K., Burger R.A., Smith H., Lee F.C., Verschraegen C.: "Angiogenesis in gynecological oncology-mechanisms of tumor progression and therapeutic targets". Int. J. Gynecol. Cancer, 2005, 15, 710. (Pubitemid 41783074)
5. Ueda M., Terai Y., Kanda K., Kanemura M., Takehara M., Futakuchi H. et al.: "Tumor angiogenesis and molecular target therapy in ovarian carcinomas". Hum. Cell., 2005, 18, 1.
6. Monk B.J., Choi D.C., Pugmire G., Burger R.A.: "Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer". Gynecol. Oncol., 2005, 96, 902.
7. Micha J.P., Goldstein B.H., Rettenmaier M.A., Genesen M., Graham C., Bader K. et al.: "A phase II study of outpatient firstline paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer". Int. J. Gynecol. Cancer, 2007, 17, 771. (Pubitemid 47063333)
8. Gordon M.S., Cunningham D.: "Managing patients treated with bevacizumab combination therapy". Oncology, 2005, 69, 25.
9. Burger R.A., Sill M., Monk B.J. et al.: "Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study". J. Clin. Oncol., 2007, 25, 5165. (Pubitemid 350237599)
10. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L. et al.: "Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis". Cancer, 2006, 107, 83.
11. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H. et al.: "Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer". J. Clin. Oncol., 2007, 25, 5180. (Pubitemid 350232248)
12. Genentech, Inc: Genentech provides update on phase II study with Avastin in platinum refractory ovarian cancer. [Press Release]. URL: http://www.gene.com/genes/news/pressrelease/index.jsp September 23, 2005.
13. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., Chi D.S.: "The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer". Gynecol. Oncol., 2008, 108, 276.
14. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L. et al.: "Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer". J. Clin. Oncol, 2005, 23, 792.
15. Melichar B., Koralewski P., Ravaud A., Pluzanska A., Bracarda S., Szczylik C. et al.: "First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma". Ann. Oncol., 2008, 19, 1470.
16. Pignata S., Breda E., Scambia G., Pisano C., Zagonel V., Lorusso D. et al.: "A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patient with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study". Crit. Rev. Oncol. Hematol., 2008, 66, 229.
17. NIH Common terminology criteria for adverse events. Washington: National Institute of Health, 2003.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S. et al.: "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada". J. Natl. Cancer Inst., 2000, 92, 205.
19. Simpkins F., Belinson J.L., Rose P.G.: "Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening". Gynecol. Oncol., 2007, 107, 118. (Pubitemid 47464553)
20. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L. et al.: "Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia". J. Clin. Oncol., 2008, 26, 76.
21. Penson R.T., Cannistra S.A., Seiden M.V., Krasner C.N., Matulonis U.A., Horowitz N.S. et al.: "Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors". Proc. Am. Soc. Clin. Oncol., 2006, 24, 18S, (abstr. 5020).
22. Rose P.G., Piver M.S.: "Intestinal perforation secondary to paclitaxel". Gynecol. Oncol., 1995, 57, 270.
23. Carter J., Durfee J.: "A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer". Gynecol. Oncol., 2007, 107, 586. (Pubitemid 350167466)